Puma Biotechnology, Inc. Aktie News
4,89 $
1,03 %
gestern
Nasdaq,
21. November, 22:00 Uhr
tracken
Puma Biotechnology, Inc. Aktie News
Positiv
Seeking Alpha
●
12 Tage alt
Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.
Neutral
Business Wire
●
15 Tage alt
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement...
Neutral
Seeking Alpha
●
15 Tage alt
Puma Biotechnology, Inc. ( PBYI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber Roger Storms Maximo F. Nougues - CFO & Principal Accounting Officer Conference Call Participants Marc Frahm - TD Cowen, Research Division Presentation Opera...
Neutral
Business Wire
●
16 Tage alt
LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.
Neutral
Business Wire
●
30 Tage alt
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.
Positiv
24/7 Wall Street
●
etwa 2 Monate alt
There's a small portion of my portfolio I allocate toward companies I'd put in the “higher risk” bucket.
Neutral
Business Wire
●
etwa 2 Monate alt
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of one inducement award to a new hire in Sept. 2025, as required by Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
●
3 Monate alt
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 25,750 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma's 2017 Employment Induceme...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
